Supriya Lifescience IPO price band, GMP, Allotment, Listing date and Price

Supriya Lifescience IPO details (16  – 20 Dec), (Price ₹ 265 to 274)

Supriya Lifescience IPO price band, GMP, Allotment, Listing date and Price
Supriya Lifescience IPO price band, GMP, Allotment, Listing date and Price

Listing date and Listing Price of Supriya Lifescience IPO:

  1. Supriya Lifescience IPO listed on BSE and NSE exchanges on – Click Here
  2. Listing Price of Supriya Lifescience IPO on NSE – Click Here
  3. Listing Price of Supriya Lifescience IPO on BSE – Click Here

Grey Market premium (GMP) price of Supriya Lifescience IPO :

Grey Market premium (GMP) price of Supriya Lifescience IPO is ₹__. Grey Market premium (GMP) of Supriya Lifescience IPO means, unofficially if someone buys or sells his application at a fixed rate irrespective of listing price. Check latest GMP of all IPOs.

  1. Check the allotment status of Supriya Lifescience IPO on the below link given by Link Intime.
  2. Supriya Lifescience IPO Allotment Link – https://linkintime.co.in/MIPO/Ipoallotment.html

Supriya Lifescience IPO Allotment link status on Link Intime can be checked by Application No or DP Client ID or PAN.

Supriya Lifescience IPO subscription status details:

QIB (Qualified Institl. Bidders)NIB (Non-institutional Investor)RII (Retail Individual Investor)Total No. of times applied
No. of shares offered79,24,52739,62,26326,41,5091,45,28,299
Day 10x0.66x11.84x2.33x
Day 20.53x2.90x25.38x5.69x
Day 331.83x161.22x56.01x71.51x
Supriya Lifescience IPO subscription status live

Supriya Lifescience IPO highlights:

Supriya Lifescience IPO bid Opens on 16  Dec 2021
Supriya Lifescience IPO bid Closes on20  Dec 2021
Post issue Modification Period21 Dec -2021 (10.00 A.M. to 11.00 A.M.)
Cut-off time for UPI Mandate Confirmation21 Dec -2021 (upto 12:00 PM)
Issue type100% Book Building
Supriya Lifescience IPO issue size₹ 700  Cr
Face value of each equity shareRs. 2
Supriya Lifescience IPO Price bandRs 265 to Rs 274 per share
Supriya Lifescience IPO market lot54 equity shares and multiples of 54
Supriya Lifescience IPO minimum order quantity54 equity shares
Pre IPO equity share of promoters of Supriya Lifescience99.98  %
Post IPO paid-up equity share of promoters of Supriya Lifescience68.24  %
QIB portion reservation in Supriya Lifescience IPO75 %
NIB portion reservation in Supriya Lifescience IPO15 %
Retail portion reservation in Supriya Lifescience IPO10 %
Retail individual bidder can apply in Supriya Lifescience IPOup to 2 lakh (200,000) – Maximum 13 Lot
Retail individual discount in Supriya Lifescience IPONA
Employees can apply in Supriya Lifescience IPOup to 5 lakh (500,000)
Employees Reservation in Supriya Lifescience IPONA
Employees Discount in Supriya Lifescience IPONA
Listing of Supriya Lifescience at ExchangesNSE, BSE
Fund raised from Anchor Investors in Pre-IPO of Supriya LifescienceNA
Registrar of Supriya Lifescience IPO issueLink Intime India Private Limited
Supriya Lifescience IPO highlights

Supriya Lifescience IPO important dates regarding bidding, allotment, listing, refund etc. :

The probable dates regarding bidding, allotment, listing, refund of Supriya Lifescience IPO are mentioned below.

Supriya Lifescience IPO opens on16.12.2021
Supriya Lifescience IPO Closes on20.12.2021
Allotment basis date of Supriya Lifescience IPO23.12.2021
Money refund date of Supriya Lifescience IPO24.12.2021
Shares of Supriya Lifescience in Demat Account27.12.2021
Supriya Lifescience IPO listing date on NSE, BSE28.12.2021
Supriya Lifescience IPO important dates regarding bidding, allotment, listing, refund etc.

How much shares of Supriya Lifescience IPO are being offered?

Type of Issue (Fresh / OFS)No. of Equity shares offeredAmount of Equity shares
Total Issue size₹ 700 Crore
Fresh Issue size₹ 200 Crore
Offer for Sale (OFS)₹ 500 Crore
Employee Reservation
No. of Equity shares offered of Supriya Lifescience IPO

Supriya Lifescience financial statements details:

31.03.202131.03.202031.03.2019
(₹ million)(₹ million)(₹ million)
Total Assets4,458.243,364.012,530.52
Total Revenue3,962.213,227.132,858.62
Profit After Tax1,238.28733.74394.24
Supriya Lifescience financial statements details

IPO Red Herring Prospectus (RHP) of Supriya Lifescience:

Click here for IPO RHP of Supriya Lifescience on SEBI website.

Objectives of the Supriya Lifescience IPO Issue: (Source – RHP)

The Fresh Issue

Our Company proposes to utilise the Net Proceeds towards funding of the following objects: 1. Funding capital expenditure requirements of our Company; 2. Repayment and/ or pre-payment, in full or part, of certain borrowings availed by our Company and 3. General corporate purposes.

Business of Supriya Lifescience: (Source – RHP)

We are one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (“APIs”), with a focus on research and development. As of October 31, 2021, we have niche product offerings of 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic. We have consistently been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 45-50% and 60-65%, respectively, of the API exports from India, between Fiscal 2017 and 2021.

We were among the largest exporters of Salbutamol Sulphate in India contributing to 31% of the API exports from India in FY 2021 in volume terms (Source: CRISIL Report). Our pharmaceutical business is organized into domestic and export sales, according to the geographies in which we operate. From April 1, 2020 until October 31 2021, our products were exported to 86 countries to 1,296 customers including 346 distributors. We have grown our API business in several countries across :

(i) Europe, which contributed to 17.40 % and 18.53 % of revenue from operation for the year ended March 31, 2021 and for the six month period ended September 30, 2021, respectively; (ii) Latin America, which contributed to 19.15 % and 12.01 % of revenue from operation for the year ended March 31, 2021 and for the six month period ended September 30, 2021, respectively; (iii) Asia (excluding India), which contributed to 29.27 % and 36.76 % of revenue from operation for the year ended March 31, 2021 and for the six month period ended September 30, 2021, respectively; (iv) North America), which contributed to 4.76 % and 2.36 % of revenue from operation for the year ended March 31, 2021 and for the six month period ended September 30, 2021, respectively; and (vi) India, which contributed to 22.53% and 26.43% of revenue from operation for the year ended March 31, 2021 and for the six month period ended September 30, 2021, respectively.

Go Back to – IPO Dashboard for other IPOs:

Disclaimer: Kindly verify from RHP and concerned company for any clarification.

If you liked this article, kindly share it on any platform, whatsapp, facebook, twitter, Linkedin etc. below to keep us motivated.

%d bloggers like this: